ImpediMed

ImpediMed PP&E per Employee

The PP&E per Employee of ImpediMed (IPD.AX) as of Oct 11, 2026 is 13,179.10 AUD. In the previous year, PP&E per Employee was 21,611.94 AUD — a change of -39.02% (lower).

PP&E per Employee

13,179.10AUD

YoY

-39.02%

Last updated:

PP&E per Employee of ImpediMed is 2025 13,179.10 AUD. PP&E per Employee of ImpediMed was 2024 21,611.94 AUD. It decreases by -39.02% lower compared to the previous year.

The ImpediMed PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2018
5,492.54 AUD
Jan 1, 2019
2,805.97 AUD
Jan 1, 2020
15,149.25 AUD
Jan 1, 2021
15,373.13 AUD
Jan 1, 2022
6,238.81 AUD
Jan 1, 2023
29,119.40 AUD
Jan 1, 2024
21,611.94 AUD
Jan 1, 2025
13,179.10 AUD
The ImpediMed PP&E per Employee history
YEARPP&E per EmployeeYoY
13,179.10AUD-39.02%
21,611.94AUD-25.78%
29,119.40AUD+366.75%
6,238.81AUD-59.42%
15,373.13AUD+1.48%
15,149.25AUD+439.89%
2,805.97AUD-48.91%
5,492.54AUD-28.96%
7,731.34AUD+30.81%
5,910.45AUD+32.89%
4,447.76AUD+46.80%
3,029.85AUD—
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

PP&E per Employee of ImpediMed is 13,179.10 AUD in 2025.

PP&E per Employee of ImpediMed changed from 21,611.94 AUD to 13,179.10 AUD, representing a -39.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee ImpediMed since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's ImpediMed historically and in real time.

Access this data via the Eulerpool API

Workforce — ImpediMed

All Key Metrics — ImpediMed